Metabolic-Associated Chronic Kidney Disease (mCKD) Screening, Diagnosis, Phenotyping and Management

Authored by Sourabh Sharma, published on 2026-11-12 13:29:04.0

The algorithm is broadly aligned with current CKD practice for risk-based screening, confirmation of chronicity, G/A staging, exclusion of alternative causes, nephrology referral, and layered cardiorenal therapy. However, metabolic-associated CKD is an emerging review-level construct rather than a guideline-standard diagnosis, and the proposed requirements of two metabolic abnormalities plus a supportive feature are not validated diagnostic criteria. The management section is substantially stronger than the proposed phenotyping framework.

Identify Metabolic and CKD Risk Factors
- Obtain BP, Anthropometry, Urinalysis, UACR, Creatinine/eGFR, and Metabolic Labs
  - AKI, Rapid Decline, Nephritic/Nephrotic Features, or Obstruction Present?
    - Start Urgent AKI or Nephrology Evaluation
    - Review Kidney Abnormalities and Repeat Testing When Stable
      - Which Kidney Abnormality Persists ≥3 Months After Excluding AKI?
        
        No CKD Confirmed: Treat Risks and Repeat Screening
        
        Assess T2DM, Adiposity, Hypertension, MASLD, and Dyslipidemia Using Table 3 Criteria
        
        Assess IR: Prediabetes, Acanthosis, Central Obesity; HOMA-IR/Fasting Insulin Count Only by Validated Assay- and Population-Appropriate Standards
        
        At Least Two Distinct Categories, With Independent T2DM/IR and No Central-Obesity Double-Counting?
        
        Primary Glomerular, Tubulointerstitial, Structural, and Hereditary Kidney Disease Excluded?
        
        Use Etiology-Specific Kidney Pathway and Manage Metabolic Comorbidity
        
        At Least One Supportive Feature: Hyperuricemia, Acidosis, CVD/Stroke, or OSA?
        
        Classify Proposed mCKD; Stage by eGFR/UACR and Metabolic Burden
        
        Start Lifestyle, Weight, BP, Glycemic, Lipid, and Smoking Management
        
        Monitor Kidney Risk and Refer High-Risk or Uncertain Cases
        
        Use RAASi in All Proposed mCKD as Tolerated
        
        Monitor Kidney Risk and Refer High-Risk or Uncertain Cases
        
        Add SGLT2i for T2DM, Albuminuric CKD, or Heart Failure When Eligible
        
        Monitor Kidney Risk and Refer High-Risk or Uncertain Cases
        
        Add GLP-1 RA for T2DM, Obesity, or Residual Cardiorenal Risk
        
        Monitor Kidney Risk and Refer High-Risk or Uncertain Cases
        
        Add nsMRA for T2DM, Persistent Albuminuria Despite RAASi, and Eligible eGFR/Potassium
        
        Monitor Kidney Risk and Refer High-Risk or Uncertain Cases
        
        Do Not Confirm Proposed mCKD; Manage CKD and Metabolic Risks
        
        Classify CKD by Established Etiology and Treat Metabolic Risks
        
        Use Etiology-Specific Kidney Pathway and Manage Metabolic Comorbidity

tos privacy